Excerpt: “This report estimates the potentially large health and economic losses in the United States associated with influenza pandemics and discusses why the most commonly used vaccine production technologies are unlikely to mitigate these losses. We estimate the value of new vaccine technologies that would make vaccines available more quickly and likely improve their effectiveness in moderating the risks of pandemics. We discuss why private market incentives may be insufficient to develop new vaccine technologies or promote the uptake of existing, faster but more expensive technologies, despite their large expected value to society. And we argue that increased utilization of, and investment in, these new technologies—along with public-private partnerships, to spur innovation—may be valuable to decrease the impact of both pandemic and seasonal influenza.”
Share